Amylyx Pharmaceuticals, Inc. (AMLX) Gross margin 2022–2024
Amylyx Pharmaceuticals, Inc. (AMLX) gross margin by fiscal year — reported gross profit divided by reported revenue.
93.2%FY2024 · since FY2022: 86.5% → 93.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | 93.2% | -0.1 pp |
| FY2023 | 93.3% | +6.8 pp |
| FY2022 | 86.5% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMLX financial trends
AMLX RevenueAMLX Net incomeAMLX Net marginAMLX Gross profitAMLX Operating incomeAMLX Operating marginAMLX Operating cash flowAMLX Free cash flowAMLX Capital expendituresAMLX Return on equityAMLX Stock buybacksAMLX Dividends paidAMLX Total assetsAMLX Total liabilitiesAMLX Shareholders’ equityAMLX overview →